A long observational study now suggests that walking as few as 3,000 steps per day may slow the progression of Alzheimer’s ...

Caren Weiner is the lead editor for consumer finance at Forbes Advisor. During her decades as a personal finance journalist, she has covered mutual funds, taxes, banking and health insurance ...

Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now recommended an ...

Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi, along ...

Eisai remains deeply committed to a patient-centered approach in Alzheimer's care and ensuring LEQEMBI (R) is available to those eligible and living with early AD in Canada. We will continue to pursue ...

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option The BLA is based on data from the ...

As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of millions ...

Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, ...

Biogen raised its full-year 2024 outlook after releasing its Q2 earnings report Thursday, which showed sales of its Alzheimer’s drug Leqembi and several newly launched drugs were slightly better than ...

LEQEMBI is the first and only approved treatment for patients with mild cognitive impairment or mild dementia stage of Alzheimer's disease (AD). AD is a type of dementia that affects memory and ...